ABSTRACT
Background Managing COVID-19-positive patients requiring surgery is complex due to perceived heightened perioperative risks. However, Canadian data in this context remains scarce. To address this gap, we conducted a multicenter cohort study in the province of Québec, the Canadian province most affected during the initial waves of the pandemic, to comprehensively assess the impact of COVID-19 symptoms, and recovery time, on postoperative outcomes in surgical patients. Methods We included adult surgical patients with either active COVID-19 at time of surgery or those who had recovered from the disease, from March 13, 2020, to April 30, 2021. We evaluated the association between symptoms or recovery time and postoperative pulmonary complications and hospital mortality using multivariable logistic regression and Cox models. Results We included 105 patients with an active infection (47 were symptomatic and 58 were asymptomatic) and 206 who had healed from COVID-19 in seven hospitals. Among patients with an active infection, those who were symptomatic had a higher risk of pulmonary complications (odds ratio = 3.19; 95% CI, from 1.12 to 9.68; p = 0.03) and hospital mortality (hazard ratio = 3.67; 95% CI, from 1.19 to 11.32; p = 0.02). We did not observe any significant effect of the duration of recovery prior to surgery on patients who had healed from their infection. Their postoperative outcomes were also similar to those observed in asymptomatic patients. Interpretation Symptomatic status should be considered in the decision to proceed with surgery in COVID-19-positive patients. Our results may help optimize surgical care in this patient population. Trial registration: ClinicalTrials.gov Identifier: NCT04458337, Registration Date: July 7, 2020.
Subject(s)
COVID-19 , Lung Diseases , Postoperative ComplicationsABSTRACT
BackgroundWhilst timely clinical characterisation of infections caused by novel SARS-CoV-2 variants is necessary for evidence-based policy response, individual-level data on infecting variants are typically only available for a minority of patients and settings. MethodsHere, we propose an innovative approach to study changes in COVID-19 hospital presentation and outcomes after the Omicron variant emergence using publicly available population-level data on variant relative frequency to infer SARS-CoV-2 variants likely responsible for clinical cases. We apply this method to data collected by a large international clinical consortium before and after the emergence of the Omicron variant in different countries. ResultsOur analysis, that includes more than 100,000 patients from 28 countries, suggests that in many settings patients hospitalised with Omicron variant infection less often presented with commonly reported symptoms compared to patients infected with pre-Omicron variants. Patients with COVID-19 admitted to hospital after Omicron variant emergence had lower mortality compared to patients admitted during the period when Omicron variant was responsible for only a minority of infections (odds ratio in a mixed-effects logistic regression adjusted for likely confounders, 0.67 [95% confidence interval 0.61 - 0.75]). Qualitatively similar findings were observed in sensitivity analyses with different assumptions on population-level Omicron variant relative frequencies, and in analyses using available individual-level data on infecting variant for a subset of the study population. ConclusionsAlthough clinical studies with matching viral genomic information should remain a priority, our approach combining publicly available data on variant frequency and a multi-country clinical characterisation dataset with more than 100,000 records allowed analysis of data from a wide range of settings and novel insights on real-world heterogeneity of COVID-19 presentation and clinical outcome.
Subject(s)
COVID-19ABSTRACT
Purpose: COVID-19 is a new disease with many undescribed clinical manifestations. Material and methods: We report herein a case of severe immune thrombocytopenic purpura (ITP) in a critical COVID-19 patient.Results: A patient presented a severe episode of immune thrombocytopenia (< 10 x 109/L) 20 days after admission for a critical COVID-19. This thrombocytopenia was associated with a life-threatening bleeding. Response to first-line therapies was delayed as it took up to 13 days after initiation of intravenous immunoglobulin and high dose dexamethasone to observe an increase in platelet count. Conclusion: COVID-19 may be associated with late presenting severe ITP. Such ITP may also be relatively resistant to first-line agents. Hematological manifestations of COVID-19, such as the ones associated with life-threatening bleeding, must be recognized.